These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 32919880)

  • 1. A consideration of convalescent plasma and plasma derivatives in the care of Severely-ill patients with COVID-19.
    Lung T; Kazatchkine MD; Risch L; Risch M; Nydegger UE
    Transfus Apher Sci; 2020 Oct; 59(5):102936. PubMed ID: 32919880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
    Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
    BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.
    Takamatsu Y; Imai M; Maeda K; Nakajima N; Higashi-Kuwata N; Iwatsuki-Horimoto K; Ito M; Kiso M; Maemura T; Takeda Y; Omata K; Suzuki T; Kawaoka Y; Mitsuya H
    J Virol; 2022 Feb; 96(4):e0155121. PubMed ID: 34818068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.
    Zimmerli A; Monti M; Fenwick C; Eckerle I; Beigelman-Aubry C; Pellaton C; Jaton K; Dumas D; Stamm GM; Infanti L; Andreu-Ullrich H; Germann D; Mean M; Vollenweider P; Stadelmann R; Prella M; Comte D; Guery B; Gachoud D; Rufer N
    Front Immunol; 2021; 12():613502. PubMed ID: 33968017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
    Wooding DJ; Bach H
    Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19.
    Raadsen MP; Gharbharan A; Jordans CCE; Mykytyn AZ; Lamers MM; van den Doel PB; Endeman H; van den Akker JPC; GeurtsvanKessel CH; Koopmans MPG; Rokx C; Goeijenbier M; van Gorp ECM; Rijnders BJA; Haagmans BL
    J Clin Immunol; 2022 Feb; 42(2):232-239. PubMed ID: 34767118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial.
    Gaborit B; Vanhove B; Vibet MA; Le Thuaut A; Lacombe K; Dubee V; Ader F; Ferre V; Vicaut E; Orain J; Le Bras M; Omnes A; Berly L; Jobert A; Morineau-Le Houssine P; Botturi K; Josien R; Flet L; Degauque N; Brouard S; Duvaux O; Poinas A; Raffi F;
    Trials; 2021 Mar; 22(1):199. PubMed ID: 33750432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperimmune anti-COVID-19 IVIG (C-IVIG) Therapy for Passive Immunization of Severe and Critically Ill COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial.
    Ali S; Luxmi S; Anjum F; Muhaymin SM; Uddin SM; Ali A; Ali MR; Tauheed S; Khan M; Bajwa M; Baig SU; Shalim E; Ahmed I; Khan AS; Quraishy S
    Trials; 2020 Nov; 21(1):905. PubMed ID: 33138867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses.
    Schlickeiser S; Schwarz T; Steiner S; Wittke K; Al Besher N; Meyer O; Kalus U; Pruß A; Kurth F; Zoller T; Witzenrath M; Sander LE; Müller MA; Scheibenbogen C; Volk HD; Drosten C; Corman VM; Hanitsch LG
    Front Immunol; 2020; 11():628971. PubMed ID: 33584731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations.
    Focosi D; Franchini M
    Expert Rev Vaccines; 2022 Jul; 21(7):877-884. PubMed ID: 34015243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
    Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
    Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of Viral Inactivation Protocols for Therapeutic Blood Products against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-COV-2).
    Belem WF; Liu CH; Hu YT; Burnouf T; Lin LT
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of SARS-CoV-2-independent immunoregulatory activity of COVID-19 convalescent plasma.
    Brox R; Achenbach S; Hackstein H
    Transfusion; 2021 Nov; 61(11):3087-3093. PubMed ID: 34546583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma.
    Ali S; Uddin SM; Ali A; Anjum F; Ali R; Shalim E; Khan M; Ahmed I; M Muhaymin S; Bukhari U; Luxmi S; Khan AS; Quraishy S
    Immunotherapy; 2021 Apr; 13(5):397-407. PubMed ID: 33557591
    [No Abstract]   [Full Text] [Related]  

  • 16. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.
    Wendel S; Kutner JM; Machado R; Fontão-Wendel R; Bub C; Fachini R; Yokoyama A; Candelaria G; Sakashita A; Achkar R; Hamerschlak N; Scuracchio P; Amaral M; Dal Ben M; Araujo D; Soares C; Camargo A; Kallás E; Durigon E; Reis LF; Rizzo LV
    Transfusion; 2020 Dec; 60(12):2938-2951. PubMed ID: 32935877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody.
    Yue S; Li Z; Lin Y; Yang Y; Yuan M; Pan Z; Hu L; Gao L; Zhou J; Tang J; Wang Y; Tian Q; Hao Y; Wang J; Huang Q; Xu L; Zhu B; Liu P; Deng K; Wang L; Ye L; Chen X
    Front Immunol; 2021; 12():751584. PubMed ID: 34630430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults.
    Self WH; Stewart TG; Wheeler AP; El Atrouni W; Bistran-Hall AJ; Casey JD; Cataldo VD; Chappell JD; Cohn CS; Collins JB; Denison MR; de Wit M; Dixon SL; Duggal A; Edwards TL; Fontaine MJ; Ginde AA; Harkins MS; Harrington T; Harris ES; Hoda D; Ipe TS; Jaiswal SJ; Johnson NJ; Jones AE; Laguio-Vila M; Lindsell CJ; Mallada J; Mammen MJ; Metcalf RA; Middleton EA; Mucha S; O'Neal HR; Pannu SR; Pulley JM; Qiao X; Raval JS; Rhoads JP; Schrager H; Shanholtz C; Shapiro NI; Schrantz SJ; Thomsen I; Vermillion KK; Bernard GR; Rice TW;
    Trials; 2021 Mar; 22(1):221. PubMed ID: 33743799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.
    Kaku Y; Kuwata T; Zahid HM; Hashiguchi T; Noda T; Kuramoto N; Biswas S; Matsumoto K; Shimizu M; Kawanami Y; Shimura K; Onishi C; Muramoto Y; Suzuki T; Sasaki J; Nagasaki Y; Minami R; Motozono C; Toyoda M; Takahashi H; Kishi H; Fujii K; Tatsuke T; Ikeda T; Maeda Y; Ueno T; Koyanagi Y; Iwagoe H; Matsushita S
    Cell Rep; 2021 Jul; 36(2):109385. PubMed ID: 34237284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-SARS-CoV-2 hyperimmune plasma workflow.
    Annamaria P; Eugenia Q; Paolo S
    Transfus Apher Sci; 2020 Oct; 59(5):102850. PubMed ID: 32540345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.